Browse Topics
How We Do It: Application of State-of-the-Art MF and PV Care Today… With An Eye Toward How New Evidence and Combinations Will be Leveraged Tomorrow
Friday, December 9th, 2022
Sheraton New Orleans Hotel | Grand Ballroom DE
Registration & Brunch: 10:15 AM – 11:00 AM CST
Scientific Session: 11:00 AM – 1:30 PM CST
Learning Objectives
- Determine factors that inform personalized treatment decisions in patients with MF, PV, and ET based on genetics, risk stratification, and symptom burden
- Outline the mechanistic rationale for the application of current and emerging therapeutic approaches for the management of MPNs
- Assess the efficacy and safety profiles of current and emerging therapeutic strategies in MPNs across lines of therapy
- Integrate recent clinical trial evidence and guidelines to individualize decisions among patients with MPNs, including management of treatment-related toxicities
State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
Friday, December 9th, 2022
New Orleans Ernest N. Morial Convention Center
Registration & Brunch: 10:15 AM – 11:00 AM CST
Scientific Session: 11:00 AM – 1:00 PM CST
Learning Objectives
- Identify risk factors for CMV and assess the impact of CMV on treatment outcomes for patients who undergo HSCT
- Outline current and emerging strategies for primary and secondary prevention of CMV infection in patients undergoing HSCT
- Devise strategies to integrate evidence-based data and expert recommendations into current clinical practice to prevent and treat CMV infection post-HSCT
- Discuss mechanisms that lead to development of resistant CMV infection as well as current and emerging strategies to address CMV infections resistant or refractory to current antiviral therapies in patients who undergo HSCT
Amplifying the Role of Accurate Diagnosis and New Therapeutic Options in the Treatment of Hemolytic Anemias
Friday, December 9th, 2022
New Orleans Ernest N. Morial Convention Center | Meeting Room: 243-245
Registration & Brunch: 10:15 AM – 11:00 AM CST
Scientific Session: 11:00 AM – 2:00 PM CST
Learning Objectives
- Determine the pathophysiological mechanisms of the rare hemolytic anemias PNH, aHUS, PKD, wAIHA, and aplastic anemia (AA)
- Explain recent diagnostic criteria for PNH, aHUS, PKD, wAIHA, and AA, with a focus on differential diagnosis methods
- Evaluate efficacy/safety data on current and emerging therapeutic options for PNH, aHUS, PKD, wAIHA, and AA
- Apply evidence from pivotal trials that assessed therapeutic options for hemolytic anemias to manage real-world clinical scenarios of patients with these diseases, including treatment-related toxicity management
Transforming How We Treat Sickle Cell Disease: Holistic Approaches to Addressing Clinical Challenges Across the Patient’s Lifespan
Friday, December 9th, 2022
Ernest N. Morial Convention Center | Room 208 - 210
Registration & Brunch: 10:15 AM – 11:00 AM CST
Scientific Session: 11:00 AM – 2:00 PM CST
Learning Objectives
- Outline the important components of successful pain management in patients with sickle cell disease (SCD)
- Evaluate the use of approved and emerging therapies alone or in combination for the management of patients with SCD
- Recognize the challenges of treating disease-related complications and comorbid conditions in patients with SCD
- Support the transition from pediatric to adult care based on an understanding of the evolving needs of patients with SCD
- Implement individualized and holistic management strategies in coordination with other specialists and health care providers involved with the patient
MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes
Friday, December 9, 2022
New Orleans Ernest N. Morial Convention Center
Registration and Lunch: 10:15 AM – 11:00 AM CST
Scientific Session: 11:00 AM – 2:00 PM CST
Learning Objectives
- Explain best practices in the assessment of MRD across hematologic malignancies, including the techniques and platforms
- Determine guideline recommendations and expert consensus to inform the use of MRD monitoring in hematologic malignancies’ settings
- Analyze the role of MRD assessment when planning treatment across the continuum of care for hematologic malignancies
- Formulate plans to integrate emerging data, sampling techniques, MRD assessment, and clinical trial data into the management of patients with hematologic malignancies.
Medical Crossfire®: How the Experts Treat Acute Lymphoblastic Leukemia- Case Discussions From Adolescent to Adult
Friday, December 9th, 2022
Ernest N. Morial Convention Center
Registration & Brunch: 10:15 AM – 11:00 AM CST
Scientific Session: 11:00 AM – 2:00 PM CST
Learning Objectives
- Utilize cytogenetic and immunophenotype characteristics to create individualized treatment strategies for adults and pediatric patients with ALL
- Assess the current and emerging role of MRD assessment in determining prognosis and in planning treatment in patients with ALL
- Evaluate the efficacy and safety of current and emerging therapies, including monoclonal antibodies and ADCs, as well as CAR T cell therapies in the management of patients with ALL
- Place updated clinical trial data and evidence-based recommendations in the context of evolving management strategies utilizing antibody-based therapy in ALL management
Bridging Clinical Gaps in Indolent and Aggressive B-Cell Lymphomas: The Investigators Demonstrate How Novel Mechanisms Will Impact Your Practice Tomorrow
Friday, December 9, 2022
11:00 AM – 2:00 PM Central Time
Learning Objectives
- Describe diagnostic and prognostic biomarkers that guide treatment planning in indolent and aggressive B-cell malignancies
- Integrate safety and efficacy data for emerging treatment options, including chemotherapy-free regimens, to clinical scenarios in patients with B-cell NHL
- Identify strategies to mitigate, monitor, and manage adverse events associated with therapeutic regimens used in the treatment of patients with B-cell NHL
- Assess recently reported and ongoing clinical trials of novel agents and therapeutic combinations for patients with indolent and aggressive B-cell malignancies
Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
Friday, December 9th, 2022
Ernest N. Morial Convention Center | Meeting Room: 243-245
Registration & Lunch: 2:15 pm – 3:00 pm CST
Scientific Session: 3:00 pm – 5:30 pm CST
Learning Objectives
- Explain the clinical presentation, cytogenetics, and pathophysiological mechanisms of BPDCN
- Apply criteria for the timely diagnosis of BPDCN, including methods for differential diagnosis, through optimization of multidisciplinary collaboration
- Assess the clinical profiles of current and emerging CD123-targeted therapeutic approaches that have been investigated for the treatment of patients with BPDCN
- Incorporate updated guidelines and pivotal trial data on current/emerging agents targeting CD123 into personalized treatment plans for patients with BPDCN
A Light at the End of the Treatment Tunnel – Exploring the Potential Role for Gene Therapy in Hemophilia B
Friday, December 9, 2022
Ernest N. Morial Convention Center | Meeting Room: 217-219
Registration and Lunch: 2:15 PM – 3:00 PM CST
Scientific Session: 3:00 PM – 6:00 PM CST
Learning Objectives
- Discuss the burden of disease for patients with hemophilia B
- Outline the current standard of care for patients with hemophilia B
- Assess clinical trial data for gene therapy for hemophilia B
- Describe models for implementation of gene therapy for hemophilia B into clinical practice
- Apply strategies to select appropriate patients for gene therapy
- Review the role of the multidisciplinary team in the management of patients receiving gene therapy for hemophilia B
Medical Crossfire®: How Do We Apply the Latest Evidence on Novel Therapies to Prevent and Treat GvHD?
Friday, December 9th, 2022
Sheraton New Orleans Hotel | Grand Ballroom DE
Registration & Dinner: 6:15 PM – 7:00 PM CST
Scientific Session: 7:00 PM – 10:00 PM CST
Learning Objectives:
- Explain the pathological mechanisms of acute and chronic GvHD underlying the rationale for therapeutic approaches to prevent and treat these post-transplant complications
- Evaluate the latest clinical evidence for therapeutic strategies investigated for the prevention and treatment of acute/chronic GvHD
- Apply strategies to promote the timely recognition and mitigation of treatment-related toxicities in patients at risk of developing GvHD or who are treated for GvHD
- Translate evidence-based approaches for the prophylaxis and treatment of acute and chronic GvHD into personalized treatment plans for patients after transplantation, to prevent or manage these post-transplant complications
"D" is for Diagnosis: Deciphering Uncommon Hematologic Disorders Through the Eyes of a Detective
Friday, December 9, 2022
Sheraton New Orleans Hotel | Grand Ballroom C
Registration & Lunch: 2:15 pm – 3:00 pm CDT
Scientific Session: 3:00 pm – 6:00 pm CDT
Learning objectives:
- Determine key processes and criteria for differential diagnosis of rare hematologic disorders
- Explain the pathophysiology of rare blood disorders and its relationship to diagnosis confirmation and treatment decisions
- Integrate emerging data and updated guidelines into personalized treatment plans for patients with rare hematologic disorders
- Apply strategies to timely monitor and mitigate disease- and treatment-related adverse events in patients with rare blood disorders
Medical Crossfire®: Maximizing Our Clinical Practices in Hodgkin Lymphoma: Integration of Recent Data Sets in Real World Settings
Friday, December 9th, 2022
New Orleans Ernest N. Morial Convention Center | Room 208-210
Registration & Lunch: 2:15 PM – 3:00 PM CST
Scientific Session: 3:00 pm – 6:00 pm CST
Learning Objectives
- Devise strategies to personalize treatment of patients with HL based on patient-related factors, risk stratification and treatment history
- Evaluate the efficacy and safety profile for current/emerging therapies among patients with advanced HL from landmark clinical trials as well as real world data across therapy lines
- Develop strategies for proactively recognizing, monitoring, and managing adverse events associated with the use of novel therapies in the management of patients with advanced HL
- Apply recent evidence from landmark trials in advanced HL to real-world scenarios encountered in the care of patients with this malignancy
Expert Illustrations & Commentaries™: Visualizing New Treatment Pathways for Anemia in Chronic Kidney Disease
Friday, December 9th, 2022
New Orleans Ernest N. Morial Convention Center
Registration & Dinner: 10:15 AM – 11:00 AM CST
Scientific Session: 11:00 AM – 12:30 PM CST
Learning Objectives
- Discuss the burden of anemia in patients with chronic kidney disease
- Review the pathophysiology of anemia in these patients
- Implement guideline-based recommendations for the evaluation of CKD-associated anemia
- Formulate individualized management plans for patients with anemia and CKD
Transfusion-Related Iron Overload– Evidence-Based Approaches to Improve Chelation Outcomes
Friday, December 9th, 2022
7:00 PM - 9:30 PM Central Time
Learning Objectives
- Outline the pathophysiologic effects of iron overload at a cellular level
- Identify end-organ effects from excess iron in transfusion-dependent patients
- Apply appropriate testing modalities to assess iron status in patients with transfusion-dependent iron overload
- Develop optimal care plans for patients with iron overload based on clinical presentation and goals of therapy